Literature DB >> 28543873

Effect of Surgery Versus Observation: Skeletal 5-Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study).

Karolina Lundstam1, Ansgar Heck2, Kristin Godang2, Charlotte Mollerup3, Marek Baranowski4, Ylva Pernow5, Turid Aas6, Ola Hessman7, Thord Rosén8, Jörgen Nordenström9, Svante Jansson10, Mikael Hellström1, Jens Bollerslev2.   

Abstract

Mild primary hyperparathyroidism (PHPT) is known to affect the skeleton, even though patients usually are asymptomatic. Treatment strategies have been widely discussed. However, long-term randomized studies comparing parathyroidectomy to observation are lacking. The objective was to study the effect of parathyroidectomy (PTX) compared with observation (OBS) on bone mineral density (BMD) in g/cm2 and T-scores and on biochemical markers of bone turnover (P1NP and CTX-1) in a prospective randomized controlled study of patients with mild PHPT after 5 years of follow-up. Of 191 patients with mild PHPT randomized to either PTX or OBS, 145 patients remained for analysis after 5 years (110 with validated DXA scans). A significant decrease in P1NP (p < 0.001) and CTX-1 (p < 0.001) was found in the PTX group only. A significant positive treatment effect of surgery compared with observation on BMD (g/cm2 ) was found for the lumbar spine (LS) (p = 0.011), the femoral neck (FN) (p < 0.001), the ultradistal radius (UDR) (p = 0.042), and for the total body (TB) (p < 0.001) but not for the radius 33% (Rad33), where BMD decreased significantly also in the PTX group (p = 0.012). However, compared with baseline values, there was no significant BMD increase in the PTX group, except for the lumbar spine. In the OBS group, there was a significant decrease in BMD (g/cm2 ) for all compartments (FN, p < 0.001; Rad33, p = 0.001; UDR, p = 0.006; TB, p < 0.001) with the exception of the LS, where BMD was stable. In conclusion, parathyroidectomy improves BMD and observation leads to a small but statistically significant decrease in BMD after 5 years. Thus, bone health appears to be a clinical concern with long-term observation in patients with mild PHPT.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BIOCHEMICAL MARKERS OF BONE TURNOVER; CLINICAL TRIALS; DXA; PARATHYROID-RELATED DISORDERS; PTH

Mesh:

Substances:

Year:  2017        PMID: 28543873     DOI: 10.1002/jbmr.3177

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  10 in total

Review 1.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 2.  [Asymptomatic primary hyperparathyroidism : Operation or observation?]

Authors:  Katja Gollisch; Heide Siggelkow
Journal:  Internist (Berl)       Date:  2021-03-12       Impact factor: 0.743

3.  Biochemical Profile Affects IOPTH Kinetics and Cure Rate in Primary Hyperparathyroidism.

Authors:  Claire E Graves; Catherine M McManus; John A Chabot; James A Lee; Jennifer H Kuo
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

Review 4.  Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2020-11-16       Impact factor: 6.514

Review 5.  MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.

Authors:  Jens Bollerslev; Camilla Schalin-Jäntti; Lars Rejnmark; Heide Siggelkow; Hans Morreau; Rajesh Thakker; Antonio Sitges-Serra; Filomena Cetani; Claudio Marcocci
Journal:  Eur J Endocrinol       Date:  2019-06-01       Impact factor: 6.664

6.  Gender differences in bone mineral density in patients with sporadic primary hyperparathyroidism.

Authors:  Danica M Vodopivec; Angelica M Silva; Dinamarie C Garcia-Banigan; Ioannis Christakis; Ashley Stewart; Kelly Schwarz; Caroline S Hussey; Roland Bassett; Mimi I Hu; Nancy D Perrier
Journal:  Endocrinol Diabetes Metab       Date:  2018-09-04

7.  Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.

Authors:  Martin B Niederle; Ursula Foeger-Samwald; Philipp Riss; Andreas Selberherr; Christian Scheuba; Peter Pietschmann; Bruno Niederle; Katharina Kerschan-Schindl
Journal:  Langenbecks Arch Surg       Date:  2019-08-26       Impact factor: 3.445

8.  European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders.

Authors:  Jens Bollerslev; Lars Rejnmark; Alexandra Zahn; Ansgar Heck; N M Appelman-Dijkstra; Luis Cardoso; Fadil M Hannan; Filomena Cetani; Tanja Sikjær; Anna Maria Formenti; Sigridur Björnsdottir; Camilla Schalin-Jantti; Zhanna Belaya; Fraser Wilson Gibb; Bruno Lapauw; Karin Amrein; Corinna Wicke; Corinna Grasemann; Michael Krebs; Eeva M Ryhänen; Ozer Makay; Salvatore Minisola; Sebastien Gaujoux; Jean-Philippe Bertocchio; Zaki K Hassan-Smith; Agnès Linglart; Elizabeth M Winter; Martina Kollmann; Hans-Georg Zmierczak; Elena Tsourdi; Stefan Pilz; Heide Siggelkow; Neil J Gittoes; Claudio Marcocci; Peter Kamenicky
Journal:  Eur J Endocrinol       Date:  2022-01-13       Impact factor: 6.664

Review 9.  Should Symptoms Be Considered an Indication for Parathyroidectomy in Primary Hyperparathyroidism?

Authors:  Alexandria D McDow; Rebecca S Sippel
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2018-06-27

10.  Identification of independent factors affecting bone mineral density after successful parathyroidectomy for symptomatic hyperparathyroidism.

Authors:  Shuai Lu; Maoqi Gong; Yejun Zha; Aimin Cui; Chen Chen; Weitong Sun; Kehan Hua; Wei Tian; Xieyuan Jiang
Journal:  BMC Endocr Disord       Date:  2020-09-14       Impact factor: 2.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.